The United States and United Kingdom Announce Zero-Tariff Pact on Prescription Drugs.

The UK and US have finalized a key bilateral deal that will ensure no levies on UK drug exports going into the US market.

Key Provisions of the Accord

Under the terms of the agreement, the UK has agreed to increase spending on pharmaceuticals through the NHS. This move secures that import taxes on these crucial exports will remain at zero for a timeframe of 36 months.

This development follows previous threats to dramatically increase import taxes on patented drug products, with figures floated reaching double the cost.

"This agreement with the UK strengthens the global environment for new treatments and brings long-overdue balance to American-British drug exports," an announcement noted.

Trade Significance

Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the US, which is by far the primary market for large UK drugmakers.

Export figures indicate that in the year prior to the third quarter, the UK shipped medicines valued at £11.1bn to the US. This amount made up a significant portion of total UK exports in that span.

"This agreement protects work, increases investment and sets the stage for the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.

Detailed NHS Changes

The pact involves several notable changes from the UK:

• Price Threshold Increase: The UK will lift the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
• Increased NHS Spending: There is a goal to raise overall NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
• Rebate Cap: The percentage drug companies must refund to the NHS to control costs will be restricted at 15%. Last year, rebates exceeded 20%.

Industry Background

The deal follows a long-running tension between the pharmaceutical industry and the ministers over medicine costs and regulatory access.

This friction were intensified by assertions that US patients were paying a premium for the identical medicines than people in the Britain and the EU.

Over the last 18 months, several significant drug company projects in the UK have been delayed or abandoned, while major investments have been pledged toward American operations.

The Science Minister publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the last ten years.